iStent: Definition, Uses, and Clinical Overview

iStent Introduction (What it is)

iStent is a tiny implanted device used in glaucoma care to help lower eye pressure.
It is placed inside the eye’s drainage angle to improve fluid outflow.
It is commonly used as a form of minimally invasive glaucoma surgery (MIGS).
It is often performed at the same time as cataract surgery in selected patients.

Why iStent used (Purpose / benefits)

The main purpose of iStent is to help reduce intraocular pressure (IOP), which is the fluid pressure inside the eye. Elevated IOP is a major risk factor for glaucoma, a group of diseases that can damage the optic nerve and lead to progressive vision loss. Lowering IOP is the most established strategy for slowing glaucoma progression, although individual outcomes vary by clinician and case.

Many glaucoma treatments lower IOP by either reducing the amount of fluid the eye makes or by improving the eye’s natural drainage. iStent is designed to improve drainage from inside the eye by creating a small bypass through tissue that commonly offers resistance in open-angle glaucoma.

Potential benefits of iStent, depending on the patient’s anatomy and glaucoma type, may include:

• Lower IOP compared with the preoperative baseline (the degree of lowering varies).
• Reduced reliance on glaucoma eye drops for some patients (not guaranteed).
• A “tissue-sparing” approach compared with traditional filtering surgeries, since MIGS generally aims to reduce surgical disruption.
• Compatibility with cataract surgery workflows, since many iStent procedures are performed during cataract removal.

It is not a vision-correction device like a contact lens or an intraocular lens implant for cataracts. Its role is primarily pressure management in appropriately selected glaucoma cases.

Indications (When ophthalmologists or optometrists use it)

Ophthalmologists typically consider iStent in scenarios such as:

• Mild to moderate primary open-angle glaucoma where additional IOP reduction is desired.
• Open-angle glaucoma in patients already planning cataract surgery, when combining procedures may be appropriate.
• Patients using glaucoma drops who would benefit from reducing medication burden, when clinically reasonable and not contraindicated.
• Ocular hypertension (elevated IOP without clear optic nerve damage) in selected cases, depending on risk profile and clinician judgment.
• Patients with an anatomically open angle on gonioscopy (a lens-assisted exam of the drainage angle).

Optometrists may not perform implantation but often help identify candidates, educate patients, and provide pre- and post-operative monitoring in collaborative care settings, depending on local scope of practice.

Contraindications / when it’s NOT ideal

iStent is not suitable for every type of glaucoma or every eye. Situations where it may be less suitable, or where another approach may be preferred, include:

• Angle-closure glaucoma or narrow angles, where the drainage angle anatomy limits access or function.
• Secondary glaucomas that primarily bypass or damage the conventional outflow pathway, such as some cases of neovascular glaucoma (abnormal blood vessels in the angle).
• Active or uncontrolled eye inflammation (uveitis), since inflammation can affect healing and device function.
• Significant scarring or abnormality of the trabecular meshwork/Schlemm’s canal system, where bypassing may not provide the desired outflow.
• Eyes with corneal clarity issues that prevent adequate angle visualization, because safe implantation depends on clear intraoperative view.
• Active eye infection or other conditions that increase surgical risk.
• Advanced glaucoma requiring very low target IOP, where clinicians may favor procedures with greater pressure-lowering potential, such as trabeculectomy or tube shunts (choice varies by clinician and case).

Final candidacy is individualized and depends on anatomy, disease severity, and treatment goals.

How it works (Mechanism / physiology)

To understand iStent, it helps to know basic aqueous humor flow. Aqueous humor is the clear fluid produced inside the eye. It circulates through the front of the eye and normally drains mainly through the trabecular meshwork into Schlemm’s canal, then into collector channels and episcleral veins.

In open-angle glaucoma, resistance to outflow often occurs at or near the trabecular meshwork, contributing to higher IOP. iStent is designed to act as a micro-bypass that provides a direct pathway from the anterior chamber (front fluid space of the eye) into Schlemm’s canal, aiming to enhance the eye’s natural “conventional” drainage.

Key points about the mechanism:

• Physiologic principle: Improve aqueous outflow via the conventional pathway by bypassing a common site of resistance.
• Anatomy involved: Anterior chamber angle, trabecular meshwork, Schlemm’s canal, and downstream collector channels.
• Onset: IOP-lowering effect is typically assessed in the early postoperative period and over subsequent follow-ups as healing stabilizes; the exact timeline varies by clinician and case.
• Duration: The implant is intended to remain in place long-term, but the magnitude of pressure control can change over time due to healing responses, disease progression, or changes in outflow pathway function.
• Reversibility: The device is implanted; “reversal” generally refers to surgical removal or additional interventions if needed, rather than a temporary effect like a medication.

Because iStent relies on the eye’s conventional drainage system, outcomes can be influenced by how functional that downstream system is in a given patient.

iStent Procedure overview (How it’s applied)

iStent implantation is a surgical intervention typically performed by an ophthalmologist, often a glaucoma or cataract surgeon. The workflow is usually structured and staged, with safety checks throughout.

A high-level overview commonly includes:

1. Evaluation / exam – Review of glaucoma history, current medications, and prior procedures. – Measurement of IOP and assessment of optic nerve and visual field status. – Gonioscopy to confirm that the drainage angle is open and to evaluate angle anatomy. – Discussion of goals such as IOP reduction, medication reduction, or both (results vary).

2. Preparation – Standard preoperative assessments and planning. – Anesthesia is commonly local (for example, topical or regional), depending on setting and patient factors. – If combined with cataract surgery, planning includes lens selection and cataract approach.

3. Intervention – If done with cataract surgery, cataract removal and intraocular lens placement are typically performed first. – The surgeon visualizes the angle using a special lens and microscope view. – iStent is inserted into the trabecular meshwork to access Schlemm’s canal. – Depending on device type, one or more stents may be implanted.

4. Immediate checks – Confirmation of stent position and stability. – Assessment for immediate complications such as bleeding in the front chamber (small microhyphema can occur with angle surgery).

5. Follow-up – Postoperative visits to monitor IOP, healing, and medication needs. – Adjustments to glaucoma drops are individualized and vary by clinician and case.

This overview is intentionally general; exact steps, sequencing, and postoperative plans differ across surgeons, devices, and patient factors.

Types / variations

The term “iStent” is often used broadly, but there are multiple device iterations. Common variations include:

• Single-stent designs
  Earlier or specific versions may involve one micro-bypass stent placed into the trabecular meshwork to access Schlemm’s canal.

• Multi-stent systems (inject-style)
  Some iStent systems are designed to deliver more than one small stent into the trabecular meshwork during the same procedure. The rationale is to access additional segments of Schlemm’s canal and collector channels, since outflow can be segmental (not evenly distributed around the angle). The exact number and design vary by model and manufacturer.

• Combined vs standalone use
  Certain iStent models are commonly used in combination with cataract surgery, while others may be considered for standalone glaucoma surgery in selected cases. Indications can differ by device labeling, regulatory region, and clinician judgment.

• Design and material differences
  Devices may differ in size, shape, lumen configuration (the internal channel), and delivery system. Material and surface characteristics also vary by manufacturer and generation, which can influence handling and tissue response.

Because device availability and approved indications vary by region and time, clinicians often use the specific product name and generation when documenting.

Pros and cons

Pros:

• Can be integrated with cataract surgery in appropriate cases, potentially streamlining care.
• Targets the eye’s natural drainage pathway rather than creating an external bleb (a fluid pocket), unlike some traditional surgeries.
• Generally considered part of MIGS, with an approach intended to reduce tissue disruption compared with filtering surgery (clinical implications vary).
• May reduce IOP and/or reduce medication burden for some patients (degree varies by clinician and case).
• Small implant size and internal location can make it cosmetically “invisible.”
• Can be combined with other glaucoma treatments over time if additional control is needed.

Cons:

• Not suitable for all glaucoma types, especially when the drainage angle is not open or the conventional pathway is not functional.
• IOP reduction may be modest compared with traditional filtering surgery in patients needing very low target pressures.
• Outcomes can be variable due to individual anatomy, healing response, and disease progression.
• As with any intraocular procedure, there are risks such as bleeding, inflammation, infection, or pressure spikes (risk profile varies by case).
• Device malposition, obstruction, or reduced effectiveness over time can occur, potentially requiring additional treatment.
• Cost and insurance coverage can be complex and vary by region, facility, and payer.

Aftercare & longevity

Aftercare following iStent implantation focuses on monitoring healing and confirming that IOP is controlled at a level appropriate for the individual’s glaucoma status. When iStent is combined with cataract surgery, aftercare often overlaps with standard cataract postoperative care, with additional attention to pressure and glaucoma medication needs.

Factors that can influence outcomes and longevity include:

• Glaucoma severity and target IOP needs: Eyes with more advanced disease may need greater pressure lowering than a trabecular bypass can reliably provide.
• Angle anatomy and downstream outflow function: Because iStent relies on Schlemm’s canal and collector channels, variability in those structures can affect results.
• Healing response: Inflammation, scarring, or debris can influence stent patency and outflow.
• Medication plan and adherence: Some patients continue drops after surgery, while others may reduce them; decisions vary by clinician and case.
• Follow-up schedule and monitoring quality: Ongoing measurements of IOP, optic nerve status, and visual fields remain important in glaucoma care regardless of procedure type.
• Comorbidities: Conditions like uveitis, diabetes-related eye disease, or prior ocular surgeries may affect healing and pressure control.

In terms of longevity, the implant is designed to remain in the eye long-term. The effect—how much it helps lower IOP—can be stable for some patients and less durable for others, depending on individual factors and glaucoma progression.

Alternatives / comparisons

iStent is one option within a broader glaucoma treatment landscape. Alternatives are selected based on glaucoma type, severity, target IOP, anatomy, and patient-specific considerations.

Common comparisons include:

• Observation/monitoring (when appropriate) vs intervention
  Some patients with ocular hypertension or very early glaucoma may be monitored closely before surgery is considered. This depends on risk factors and clinical findings.

• Medications (eye drops) vs iStent
  Drops can reduce IOP by decreasing fluid production or increasing outflow. They are non-surgical but require ongoing use and may cause side effects or adherence challenges. iStent aims to reduce IOP without relying solely on daily drops, but results vary and drops may still be needed.

• Laser trabeculoplasty (e.g., SLT) vs iStent
  Selective laser trabeculoplasty (SLT) is an office-based laser treatment that targets the trabecular meshwork to improve outflow. SLT does not involve an implant. iStent is an intraocular procedure, often combined with cataract surgery, and may be chosen based on timing, anatomy, and clinician preference.

• Other MIGS procedures vs iStent
  MIGS is a category that includes multiple approaches: trabecular stents, canal-based scaffolds, trabecular tissue removal (trabeculotomy/excisional procedures), and suprachoroidal or subconjunctival pathways (availability varies). Each differs in mechanism, typical IOP reduction range, and risk profile.

• Traditional filtering surgery (trabeculectomy) or tube shunts vs iStent
  These procedures can achieve lower IOP levels in many cases but are generally more invasive and often involve a filtering bleb or implanted tube. They are commonly considered when glaucoma is advanced or when lower target IOP is necessary.

No single option is universally “better.” Treatment selection is individualized, and clinicians often sequence therapies over time as glaucoma changes.

iStent Common questions (FAQ)

Q: Is iStent the same thing as cataract surgery?
No. Cataract surgery removes the cloudy natural lens and replaces it with an artificial intraocular lens. iStent is a glaucoma implant that aims to improve fluid drainage and lower IOP; it is often performed during cataract surgery but serves a different purpose.

Q: Does iStent improve vision?
iStent is not designed to sharpen vision. Any vision improvement after a combined procedure is typically related to cataract removal rather than the stent. Its goal is pressure management to help reduce risk of glaucoma-related damage over time.

Q: Does the iStent procedure hurt?
During surgery, anesthesia is commonly used to keep the eye comfortable. Afterward, patients may notice irritation, scratchiness, or mild discomfort, especially if cataract surgery was also performed. The intensity and duration vary by clinician and case.

Q: How long does iStent last?
The implant is intended to stay in the eye long-term. However, the pressure-lowering effect can change over time due to healing response, changes in the outflow system, or glaucoma progression. Follow-up measurements are used to assess durability in each individual.

Q: Is iStent “safe”?
All intraocular surgeries carry risks, including infection, bleeding, inflammation, and changes in eye pressure. iStent is generally categorized as MIGS, which is designed to be less disruptive than traditional filtering surgery, but “safety” depends on patient factors, surgeon experience, and the specific device used.

Q: Will I be able to stop my glaucoma drops after iStent?
Some patients reduce the number of drops, and some continue drops after surgery. The goal can be IOP reduction, medication reduction, or both, but outcomes are variable. Decisions about drops are typically made based on postoperative IOP and optic nerve status.

Q: What is the recovery like, and how soon can people drive or return to screens?
Recovery varies depending on whether iStent was combined with cataract surgery and on individual healing. Vision may be blurry early on, and sensitivity to light can occur. Return to driving or prolonged screen use depends on visual clarity and comfort, and timing varies by clinician and case.

Q: Can iStent be done without cataract surgery?
Some iStent models and clinical scenarios allow standalone implantation, while other uses are more commonly combined with cataract surgery. Eligibility depends on device indication, anatomy, and clinical goals. Availability can also vary by region and surgeon preference.

Q: How much does iStent cost?
Cost varies widely based on country, insurance coverage, facility fees, whether it is combined with cataract surgery, and the specific device used. Some patients have significant coverage while others face higher out-of-pocket costs. Exact pricing is not uniform.

Q: If iStent doesn’t lower pressure enough, what happens next?
Additional treatment options can include medications, laser therapy, other MIGS procedures, or more traditional glaucoma surgeries. The next step depends on the level of IOP control needed and the overall glaucoma status. Clinicians typically plan follow-up pathways with multiple options in mind.